Courier Health raises $50M to fix broken patient journeys with AI in biopharma

Patients are getting prescribed life-changing drugs—and then getting lost in the system. Delays in insurance approvals, disconnected support teams, and fragmented data often turn treatment into a slow, frustrating process.

For biopharma companies, the breakdown doesn’t happen in the lab. It happens after the prescription, where coordination across providers, pharmacies, and payers still runs on patchwork systems.

Courier Health is building a business around fixing that gap. The New York-based healthtech startup just raised $50 million in a Series B round led by Oak HC/FT, with participation from Norwest and Work-Bench, to connect the systems behind the patient experience and bring structure to a process that still feels disjointed.

The problem is widespread. A 2026 industry report found nearly 60% of biopharma companies say their data is fragmented or hard to use. Fewer than 10% believe they have the maturity needed to apply AI meaningfully. That disconnect shows up in delayed treatment starts, missed follow-ups, and patients dropping off therapy earlier than expected.

Courier Health’s platform is designed to sit at the center of that workflow. It connects data across the full patient lifecycle, from education and enrollment to benefits verification, prior authorization, therapy initiation, and long-term adherence. The system flags patients at risk of falling off treatment, coordinates actions across teams, and uses AI agents to handle repetitive operational tasks that slow things down.

“Our vision is to rewrite the patient experience in healthcare, starting with simplifying and coordinating complex patient journeys for those who depend on innovative medicines,” said Danny Sigurdson, Founder and CEO of Courier Health. “Our partnership with Oak HC/FT provides the strategic support and capital to accelerate our mission, scale our platform and agentic AI capabilities, and continue investing in our world-class team to ensure our customers are successful. When our customers are successful, patients achieve better health outcomes, and that is our north star.”

The bet from investors is that patient experience is no longer a secondary layer. It’s becoming core infrastructure. Life sciences companies have long relied on disconnected tools to manage patient engagement, leaving teams with limited visibility across the journey.

“Healthcare, especially life sciences, has long lacked a dedicated, purpose-built platform to manage patients,” said Billy Deitch, Partner, Oak HC/FT. “True patient-centricity is often promised but rarely delivered, and Courier Health changes that narrative. They provide essential infrastructure and an incredibly thoughtful AI strategy that biopharma is excited to adopt at a rapid pace. Oak is proud to partner with Danny and his team as they redefine the standard for the patient experience.”

Courier Health says demand is rising quickly. In 2025, the company increased the number of customers and therapies supported on its platform by more than 400% and doubled its headcount to keep pace with adoption. That growth reflects a broader shift across the industry, where improving patient access and adherence is becoming as important as developing the therapies themselves.

The new funding will go into product development and hiring, with a focus on expanding its AI capabilities and reaching more biopharma customers. The company is aiming to turn a fragmented process into a coordinated system that gives teams clearer visibility and control over patient outcomes.

That’s a difficult challenge in a system filled with legacy tools and competing stakeholders. Still, the direction is clear. As more therapies reach the market, the next question isn’t just whether they work—it’s whether patients can actually access and stay on them.

Courier Health is betting that fixing that part of the equation is where the real impact—and opportunity—lies.